Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

Optimi Health to Present at the ThinkEquity Conference

Optimi Health to Present at the ThinkEquity Conference

Optimi Health, a commercial-stage pharmaceutical company specializing in regulated psychedelic drug products for mental health therapies, announced that it will present at the ThinkEquity Conference on October 15, 2026. The presentation will cover a corporate overview and provide opportunities for one-on-one investor meetings.

Onfolio Holdings Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Onfolio Holdings Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Onfolio Holdings Inc. has received an extension from Nasdaq until November 23, 2026, to regain compliance with the minimum stockholders' equity requirement of $2.5 million. The company previously failed to meet this standard and did not satisfy alternative compliance measures. Nasdaq will continue to monitor Onfolio's progress, with potential delis…

Lucas GC Limited Announces 1H 2026 Financial Results: Revenue at US$35.74 million with Increases in Gross Margin

Lucas GC Limited Announces 1H 2026 Financial Results: Revenue at US$35.74 million with Increases in Gross Margin

Lucas GC Limited, a Nasdaq-listed AI-driven PaaS company targeting the HR and insurance sectors, announced its 1H 2026 results showing a 36.6% revenue decline to US$35.7 million largely due to decreases in outsourcing and recruitment services amidst macroeconomic headwinds. However, the company improved gross margin by 1.7% to 35.4% and increased n…

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

BioCardia, Inc. announced its presentation of the CardiAMP HF II trial design at the 2026 Heart Failure Society of America Annual Scientific Meeting. The multicenter, double-blind randomized controlled trial evaluates high dose autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. The trial aims to support regu…

LPL Financial Welcomes Legacy Financial Group

LPL Financial Welcomes Legacy Financial Group

LPL Financial announced that Legacy Financial Group, led by financial advisor Brad Jerome and managing approximately $175 million in assets, has joined LPL's broker-dealer and Registered Investment Advisor platforms. The move aims to support Legacy Financial Group's growth with LPL's robust technology, investment platforms, and advisor support. The…

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences announced it will deliver its first-ever company presentation at BIO-Europe 2026, showcasing clinical and nonclinical data on its novel FABP5 inhibitor ART26.12. The company highlighted the drug's favorable safety profile, dosing flexibility, and potential efficacy in treating chemotherapy-induced peripheral neuropathy and osteoa…

Tessera: Zorronet Reports Growing Operational Deployments of Its Natural-Language AI Platform in Defense and Critical Infrastructure

Tessera: Zorronet Reports Growing Operational Deployments of Its Natural-Language AI Platform in Defense and Critical Infrastructure

Tessera Defense and Homeland Security's subsidiary, Zorronet Ltd., reports significant operational deployments of its advanced AI intelligence platform integrating natural-language processing, video analytics, and no-code tools. The platform is being adopted by customers in critical infrastructure, defense, public safety, transportation, and energy…

WISeSat.Space to Ring the Nasdaq Opening Bell on October 9 and Highlight Secure Space Infrastructure Strategy at  Convene Quantum Space Security Roundtable

WISeSat.Space to Ring the Nasdaq Opening Bell on October 9 and Highlight Secure Space Infrastructure Strategy at Convene Quantum Space Security Roundtable

WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) will ring the Nasdaq Opening Bell on October 9, 2026, to mark its listing and outline its strategy for developing quantum-resilient space communication infrastructure. The company will also host a Quantum Space Security Roundtable featuring experts in space, quantum tech, and cybersecurity to discuss prot…

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Clearmind Medicine Inc. announced that it has submitted recommendations to the U.S. FDA advocating for new regulatory pathways and broader patient access to non-hallucinogenic psychedelic-derived neuroplastogens for treating Alcohol Use Disorder and other neuropsychiatric conditions. The company highlighted promising clinical trial results from Yal…

Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

Wellspect HealthCare, a subsidiary of Dentsply Sirona, announced that its Surity™ portfolio of urinary management products is now eligible for traditional Medicare reimbursement for medically necessary cases. This milestone expands access to non-invasive urinary incontinence solutions for over 13 million affected patients in the U.S., reducing barr…

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx has enrolled the first patient in the PRISM-TAMP investigator-initiated trial, evaluating neoadjuvant intra-arterial gemcitabine delivery via their TAMP platform for borderline resectable pancreatic ductal adenocarcinoma. This marks a clinical expansion beyond their ongoing Phase III for locally advanced pancreatic cancer, with results ant…

TOMI Environmental Solutions Confirms Readiness to Support Biosecurity Preparedness and Front-Line Response Worldwide

TOMI Environmental Solutions Confirms Readiness to Support Biosecurity Preparedness and Front-Line Response Worldwide

TOMI Environmental Solutions, trading on NASDAQ under TOMZ, confirmed its preparedness to support global biosecurity efforts through its disinfection technology and services. The company highlighted its capability to assist hospitals, laboratories, and government agencies in response to potential outbreaks, using its SteraMist systems. This announc…

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Propanc Biopharma announced promising preclinical data for its lead candidate PRP, demonstrating over 90% tumor growth inhibition, reduced metastases, and tumor microenvironment remodeling in pancreatic ductal adenocarcinoma models. PRP offers a distinct mechanism from Revolution Medicines' FDA-approved daraxonrasib, targeting cancer pathways not a…